<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821911</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDPC-5</org_study_id>
    <nct_id>NCT01821911</nct_id>
  </id_info>
  <brief_title>The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use</brief_title>
  <official_title>Phase 4 Study of Speeda® Rabies Vaccine for Human Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to achieve the post-marketing safety and immunogenicity
      research of Speeda® rabies vaccine for human use from Chengda Bio
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the research is to compare the two immune procedures. The investigators plan to
      enroll 10500 participants signed the informed consent who separately inject by Zagreb or
      Essen procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Adverse Events of the rabies vaccine each injection</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titre of the subject on 0、7、14、42、180、365</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10500</enrollment>
  <condition>Rabies Vaccine Allergy</condition>
  <condition>Vaccination Adverse Event</condition>
  <condition>Anti-D Antibodies</condition>
  <arm_group>
    <arm_group_label>Zagreb2-1-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection on day 0、7、21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Essen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection on day 0、3、7、14、28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zagreb2-1-1</intervention_name>
    <description>Injection on day 0、7、21</description>
    <arm_group_label>Zagreb2-1-1</arm_group_label>
    <arm_group_label>Essen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Essen</intervention_name>
    <description>Injection on day 0、3、7、14、28</description>
    <arm_group_label>Zagreb2-1-1</arm_group_label>
    <arm_group_label>Essen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent/legal acceptable representatives of children or the adult participants are
             willing and able to understand the protocol requirements and provide informed consent
             signed

          -  Participant is considered to be in good health including the body and mental status on
             the basis of reported medical history and limited physical examination and live in
             local ≥ 12 months

          -  Participant body temperature ≤ 37.0℃

          -  Participant without preventive inoculation of rabies vaccine(only limited in
             immunogenicity subgroup)

        Exclusion Criteria:

          -  Three-level exposure

          -  Known allergy to any constituent of the vaccine

          -  Reported the history of allergies, convulsions, epilepsy, mental illness and brain
             disease and clear serious systemic reaction

          -  Known bleeding disorder or suspected impairment of immunologic function, or receipt of
             immunosuppressive therapy or immunoglobulin since birth

          -  Participation in any other interventional clinical trial

          -  An acute illness with or without fever (temperature ＞ 37.0℃) in the latest week
             preceding enrollment in the trial

          -  Inoculated other vaccines, immunoglobulin or investigational drugs within 4 weeks
             prior to participation in the study

          -  Reported clearly the infection of the upper respiratory tract with 6 months Clinical
             Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract,
             nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor

          -  Any condition which, in the opinion of the investigator, would pose a health risk to
             the subject or interfere with the vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nianmin Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chaoyang District Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong Centers for Disease Control and Prevention</name>
      <address>
        <city>Zhaoqing</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Centers for Disease Control and Prevention</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang District Centers for Disease Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

